Oct, 23, 2018 Astellas and BANDAI NAMCO Entertainment to Jointly Develop Smartphone Exercise Support App
Aug, 10, 2018 Astellas Announces Acquisition of Quethera - Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma -
May, 10, 2018 Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan
Mar, 6, 2018 Tottori University and Astellas Enter into the Global Exclusive Licensing Agreements for Immunostimulating Gene Loading Oncolytic Virus
Feb, 14, 2018 Astellas Acquires Universal Cells, Inc.
Dec, 1, 2017 Astellas Acquires Mitobridge Under Existing Collaboration
Apr, 3, 2017 Astellas to Acquire Ogeda SA
Feb, 28, 2017 Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease
Feb, 27, 2017 Kyowa and Astellas enter into an Agreement for Exclusive Distribution and Promotion of Extended-Release Tablets of Quetiapine Fumarate in Japan
Jan, 31, 2017 Astellas Executes License Agreement with Auration Biotech for the Development and Commercialization of AU-935
Dec, 12, 2016 Astellas Announces Transfer of Qutenza to Grünenthal
Oct, 28, 2016 Astellas to Acquire Ganymed Pharmaceuticals -Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage -
Sep, 28, 2016 Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area
Jul, 28, 2016 CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN ALS
Jun, 23, 2016 The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreement for Rice-Based Oral Vaccine
May, 25, 2016 Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.
Feb, 01, 2016 Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa
Dec, 11, 2015 Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy
Nov, 20, 2015 Astellas Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
Nov, 18, 2015 Presentation for Astellas to Acquire Ocata Therapeutics
Nov, 11, 2015 Astellas Transfers Its Global Dermatology Business to LEO Pharma
Oct, 09, 2015 Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax™ Products for Allergic Disease
Sep, 30, 2015 Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain
Jun, 02, 2015 Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Celiac Disease and Type 1 Diabetes -
Apr, 22, 2015 Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics - Exclusive Collaboration Includes Option for Astellas to Acquire Potenza -
Apr, 15, 2015 MSD and Astellas sign a memorandum of understanding regarding co-development and co-commercialization of combination product of JANUVIA® and Suglat®, oral treatments for type 2 diabetes
Apr, 03, 2015 MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia
Jan, 30, 2015 Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis
Dec, 24, 2014 CYTOKINETICS AND ASTELLAS ANNOUNCE EXPANSION OF COLLABORATION FOR DEVELOPMENT OF CK-2127107 IN SPINAL MUSCULAR ATROPHY AND OTHER NEUROMUSCULAR INDICATIONS
Nov, 04, 2014 DANA-FARBER CANCER INSTITUTE AND ASTELLAS ANNOUNCE - Focus on research and development for small molecule inhibitors of oncogenic K-Ras- the most commonly mutated oncogene in human cancers -
Oct, 14, 2014 ASTELLAS ANNOUNCES RESEARCH COLLABORATION WITH HARVARD MEDICAL SCHOOL INVESTIGATOR FOR TREATMENT OF RETINAL DEGENERATION - AIMing to establish a new treatment for ophthalmologic diseases -
Aug, 08, 2014 CANCER RESEARCH UK AND CANCER RESEARCH TECHNOLOGY JOIN FORCES WITH ASTELLAS ON AUTOPHAGY TO FIND NEW CANCER TREATMENTS
Jan, 06, 2014 ASTELLAS TO FORM STRATEGIC PARTNERSHIP WITH CLEARPATH TO BUILD VACCINE PORTFOLIO -In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics-
Dec, 25, 2013 Astellas and IBL Concludes Co-Research Agreement Regarding Pharmaceutical Applications of Recombinant Human Proteins Made Using transgenic Silkworms
Oct, 07, 2013 ASTELLAS AND MITOKYNE TO PURSUE MITOCHONDRIA-RELATED DISEASE THERAPIES - Collaboration Will Focus on Expanding the New Frontier of Mitochondria-related Disease -
Sep, 02, 2013 Astellas and MSD Enter Co-Promotion Agreement in Japan for Ipragliflozin, SGLT2 Inhibitor for Treatment of Type 2 Diabetes
Jun, 28, 2013 Seattle Genetics and Agensys, an affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration
Jun, 26, 2013 CYTOKINETICS AND ASTELLAS ANNOUNCE COLLABORATION IN THE FIELD OF SKELETAL MUSCLE ACTIVATION
May, 29, 2013 AMGEN AND ASTELLAS ANNOUNCE JAPAN ALLIANCE Innovative Joint Venture to Address Unmet Medical Needs of Patients in Japan
May, 07, 2013 Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
Apr, 05, 2013 Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology
Oct, 02, 2012 Astellas Enters License Agreement with Janssen to Develop and Commercialize ASP015K, an Astellas' Oral JAK Inhibitor for Immunologic Diseases
Jun, 04, 2012 Astellas and Drais Partner To Develop Second Astellas Compound through Seldar
Apr, 25, 2012 Astellas and Drais Partner To Develop Astellas Compound through Telsar
Mar, 30, 2012 Optimer Pharmaceuticals, Inc. and Astellas Pharma Inc. Enter Collaboration to Commercialize Fidaxomicin for Clostridium difficile Infection in Japan
Feb, 20, 2012 Astellas Pharma & Sanwa Kagaku Kenkyusho Establish Strategic Alliance in Japan's Pharmaceutical Market for Kidney Diseases
Feb, 01, 2012 UCB and Astellas announce agreement to jointly develop and commercialize Cimzia® (certolizumab pegol) in Japan
Dec, 21, 2011 AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion
Nov, 08, 2011 Collaborative Research Launched to Explore Novel Drug Targets for Alzheimer's Disease RIKEN Brain Science Institute and Astellas Pharma Form Strategic Alliance for New Drug Discovery
Sep, 05, 2011 Astellas Pharma signs a license agreement with Evec for a fully-human antibody
Jul, 27, 2011 Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico andthe United States from Astellas (pdf 30KB)
Jul, 15, 2011 Vical and Astellas Announce Worldwide License Agreements for TransVax™ Cytomegalovirus Vaccine
Jun, 30, 2011 Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million
May, 17, 2011 Astellas and Maxygen Announce Completion of Acquisition of Perseid by Astellas
May, 17, 2011 Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia
Dec, 08, 2010 Astellas Pharma Enters Strategic Equity Deal with Cytori ; To Purchase $10 Million in Equity at $7.00 per Share
Nov, 01, 2010 Astellas Pharma Inc.: Enter into Option Agreement with Alavita to Acquire Diannexin Assets
Oct, 19, 2010 Astellas and ASKA Enter into License Agreement for AKP-002
Sep, 30, 2010 Astellas and UMN Pharma enter into the definitive agreement for UMN Pharma's Cell Culture Based Influenza Vaccine Programs in Japan
Jul, 28, 2010 Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology through 2023
May, 17, 2010 Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
Feb, 24, 2010 Entered into Global Partnership with Basilea for an Azole Antifungal Agent Isavuconazole
Dec, 18, 2009 Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
Nov, 24, 2009 Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration
Nov, 10, 2009 Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
Oct, 28, 2009 Astellas and Medivation Enter into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
Aug, 26, 2009 Pfizer and Astellas Announce Co-promotion Agreement for Caduet® Combination Tablets
Aug, 04, 2009 AstraZeneca and Astellas Announce Co-Promotion Alliance for the Inhalant Combination Drug of Budesonide and Formoterol (generic names) for the Treatment of Asthma in Japan
Aug, 03, 2009 Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved SumavelTM DoseProTM -- Novel Product Recently Approved by the FDA for Treatment of Acute Migraine and Cluster Headache --
Jul, 01, 2009 Astellas Announces Joint Venture with Maxygen to Develop Protein Pharmaceuticals
Jun, 23, 2009 NeurogesX and Astellas Enter Commercialization Agreement for Qutenza TM
